MSc; for the Stroke Oxygen Study Investigators and the Stroke Oxygen Study Collaborative Group IMPORTANCE Hypoxia is common in the first few days after acute stroke, is frequently intermittent, and is often undetected. Oxygen supplementation could prevent hypoxia and secondary neurological deterioration and thus has the potential to improve recovery.
H ypoxia is common during the first days after an acute stroke 1 and associated with higher rates of neurological deterioration, 2 death and institutionalization, 3 and greater mortality. 4 While cells in the ischemic penumbra are only viable for a few hours, brain cells beyond the ischemic core and penumbra remain at risk of delayed cell death for several days owing to vasogenic edema, inflammation, and programmed cell death, particularly if metabolic disturbances are compounded by hypoxia. [5] [6] [7] Continuous monitoring is associated with better outcomes, 8 but even in intensively monitored patients, hypoxia is not always identified and treated. Adverse outcomes were observed to be increased when only some desaturations of less than 90% were treated with oxygen and reduced when all were treated. 3 Supplemental oxygen could improve outcomes by preventing hypoxia and secondary brain damage but could also have adverse effects. 9 These include vasoconstriction and pulmonary toxicity with high concentrations, 9 respiratory tract infection due to contamination of the nasal tubes, the tubing acting as an impediment to mobilization, stress, and the direct effects of oxygen on vascular tone and blood pressure. 10 Three small trials of short-term (≤12 hours) high-flow (10 to 45 L/min) therapeutic oxygen, aimed at generating supraphysiological blood oxygen levels, have not shown improved outcomes. [11] [12] [13] A larger trial (n = 550) using low-dose supplemental oxygen (3 L/min for 24 hours) also showed no benefit, 14 but early neurological recovery was improved in a study giving low-dose oxygen over 72 hours. 15 The primary aim of the Stroke Oxygen Study (SO 2 S) was to determine whether low-dose oxygen therapy during the first 3 days after an acute stroke improves outcome compared with usual care (oxygen only when needed). Because oxygen may restrict mobility and interfere with daytime activities, the secondary hypothesis was that oxygen given at night only, when hypoxia is most likely, is more effective than continuous oxygen supplementation.
Methods

Study Design
This was a multicenter randomized clinical trial of oxygen supplementation with single-blind outcome assessment. The protocol and statistical analysis plan (Supplement 1 and Supplement 2), 16, 17 and data collection forms 18 are published. Fully informed written or witnessed oral consent was given by the participants or, if they did not have capacity to consent, by a legal representative. The protocol was approved by the North Staffordshire Research Ethics Committee (06/Q2604/109).
Participants
Adults (aged ≥18 years) with a clinical diagnosis of acute stroke within 24 hours of hospital admission (136 participating centers in the United Kingdom), who had no clinical indications for or contraindications to oxygen treatment or any concomitant condition likely to limit life expectancy to less than 12 months were eligible (see eAppendix in Supplement 3 for definition of acute stroke).
Randomization and Interventions
Participants were allocated 1:1:1 via central web-based minimized randomization 19 to (1) continuous oxygen supplementation;
(2) nocturnal oxygen supplementation only; or (3) no routine oxygen (control). The factors for which imbalances were minimized were the Six Simple Variable prognostic index for independent survival at 6 months 20 (cutoffs: ≤0.1, >0.1 to ≤0.35, >0.35 to ≤0.70, >0.70), oxygen treatment before randomization (yes, no, unknown), baseline oxygen saturation on air (<95%, ≥95%), and time since stroke onset (cutoffs: ≤3, >3 to ≤6, >6 to ≤12, >12 to ≤24, >24 hours). Stroke onset was defined as the last time well for wakeup strokes. No blocking was used. Oxygen was administered per nasal tubes either continuously (day and night) during the first 72 hours after randomization or overnight (21:00 hours to 07:00 hours)for3nights.Oxygenwasgivenataflowrateof3L/minif baseline saturation was 93% or below or at a flow rate of 2 L/min if baseline saturation was greater than 93%. In the control group, no routine oxygen supplementation was given. Vital signs were observed at least 4 times per day, with any abnormal findings treated independently of trial allocation. Patients requiring oxygen in the control group, patients in the nocturnal oxygen group during the day, or patients needing changes in oxygen dosage for clinical reasons were given the appropriate concentration of oxygen irrespective of treatment group. In addition, for 4144 patients recruited in the latter half of the study, spot checks of treatment adherence were undertaken at midnight and 6 AM.
Outcomes and Blinding
Outcomes were assessed at 1 week by a member of the local research team and at 90 days via postal questionnaire. Telephone interviews were conducted with nonresponders or to clarify unclear or missing answers. The primary outcome was the modified Rankin Scale (mRS) 21 score (disability range, 0 [no symptoms] to 6 [death] ; minimum clinically important difference 1 point) assessed at 90 days. Secondary outcomes were number of participants with neurological improvement (≥4-point decrease on the National Institutes of Health Stroke Scale [NIHSS]) 22, 23 between randomization and day 7, the highest and lowest oxygen saturations within the first 72 hours, and mortality at 1 week. Further secondary outcomes at 90 days were mortality, number of participants alive and independent (mRS ≤2), number of participants living at home, Barthel Index
Statistical Analysis
The trial was designed to answer 2 key questions: whether oxygen supplementation improves outcome (mRS at 90 days) and whether giving oxygen at night is more effective than giving it continuously. The main comparisons, therefore, were of the 2 combined oxygen groups (continuous and nocturnal only) vs control, and of continuous oxygen vs nocturnal-only oxygen. The statistical analysis plan describes the analysis methods in detail (Supplement 1 and Supplement 2). 17 The mRS was analyzed by ordinal logistic regression, which yields a common odds ratio (OR) for a move from one level to the next better (lower) level with an OR more than 1.00 indicating an improvement. For this and other outcome variables, a primary unadjusted analysis and a secondary covariate-adjusted analysis were performed. Adjusted analyses incorporated the following covariates: age, sex, baseline NIHSS score, baseline oxygen saturation, and the Six Simple Variable prognostic index for 6-month independence (or for analysis of mortality, the Six Simple Variable prognostic index for 30-day survival). Sensitivity analysis for the mRS used multiple imputation of missing values (using a chained equations method with 20 imputed data sets). Additional imputations were performed to allow for the possibility that data were missing not at random and were either better or worse than expected; missing values were thereby replaced by either very good (ie, lowest) or very poor (ie, highest) scores on the mRS as appropriate (eTable 3 in Supplement 3). Subgroups, for the mRS only, were analyzed by an interaction term and were predefined in the statistical analysis plan. 17 For continuous outcomes, means and standard deviations or medians and interquartile ranges (IQRs) are reported, as appropriate. Unadjusted analyses used unrelated t tests, with the mean difference between treatments and corresponding CIs reported. The adjusted analysis used analysis of covariance, with the covariates specified earlier included in the analysis. For dichotomous outcomes, percentages were compared across the treatment comparisons using a χ 2 test (unadjusted analyses). Adjusted analyses of dichotomous outcomes used binary logistic regression, with the covariates listed earlier; ORs and CIs are reported. All analyses were by intention to treat, ie, according to the treatment group to which participants were allocated, irrespective of treatment actually received. Statistical significance was set at a P value of less than or equal to .05 with 95% CIs for the primary outcome and at a P value of less than or equal to .01 with 99% CIs for secondary outcomes. All reported P values are 2-sided. The main analysis was performed in SAS software for Windows, version 9.4 (SAS Institute Inc), and IBM SPSS for Windows, version 22 was used for sensitivity analyses.
Figure 1. Flow of Participants Enrolled in the Continuous
Interim analyses of safety and effectiveness were reviewed annually by an independent data monitoring and safety committee. No α-spending adjustments were made.
Results
Participants
A total of 8003 participants from 136 collaborating centers in the United Kingdom were randomized and followed up between April 24, 2008 , and January 27, 2015, (Figure 1 ). Baseline demographic and clinical characteristics, including stroke severity and oxygen saturation at randomization, were well-balanced in the Table 1 ). The mean (SD) age of participants was 72 (13) years, 4398 (55%) were men, and 7332 (92%) could undertake activities of daily living independently before the stroke. The mean (SD) NIHSS score was 7 (6) and the median score was 5 (IQR, 3 to 9). Prior to randomization, oxygen had been given to 1601 (20%) participants either in the ambulance or in the hospital. Patients were enrolled at a median of 20:43 hours (IQR, 11:59 to 25:32 hours) after symptom onset. The mean (SD) oxygen saturation at randomization was 96.6% (1.7%). All participants had a clinical diagnosis of stroke at the time of enrollment. The final diagnosis at 7 days was ischemic stroke in most cases (n = 6555; 82%), 588 (7%) had a primary intracerebral hemorrhage, and 294 (4%) were strokes without computed tomography diagnosis. There were 168 (2%) participants who were given a final diagnosis of transient ischemic attack, and 292 (4%) were found to have other nonstroke diagnoses with missing data in 106 (1%). Informed consent was provided by 6991 (87%) participants, and 1012 (13%) had consent given by a relative, caregiver, or an independent legal representative (eTable 1 in Supplement 3). Of the participants who were unable to personally provide consent and were included by a representative, 6 (0.1%) refused consent at the 1-week reassessment and 22 (2%) refused at the 90-day assessment and were withdrawn.
Treatment Adherence
Adherence was similar in the continuous oxygen group (2158 [81%]) and the nocturnal oxygen group (2225 [83%]), all of whom were prescribed the full course of treatment (eTable 2 in Supplement 3). Use of oxygen was discontinued prematurely among 433 (16%) participants in the continuous oxygen group and 361 (14%) in the nocturnal oxygen group. The most common reason for early discontinuation of oxygen was discharge from the hospital. In the control group, trial oxygen was recorded as being given to 33 (1.2%) participants, with no recording of whether oxygen was given among 406 (15%).
Effect on Oxygenation
Oxygen treatment resulted in a significant increase of 0.8% in the highest oxygen saturation and 0.9% in the lowest oxygen saturation during the 72 hours of the intervention period in the continuous oxygen group compared with controls, and of 0.5% in the highest oxygen saturation and 0.4% in the lowest oxygen saturation during the 72 hours of the intervention period in the nocturnal oxygen group compared with controls (P < .001 for all comparisons; Table 2 ). Significantly more participants in the combined oxygen groups (n = 463 [9%]) required oxygen for clinical reasons during the intervention period than in the control group (n = 176 [7%]) (P < .001). Similarly, more participants in the continuous oxygen group (n = 254 [10%]) required oxygen than in the nocturnal oxygen group (n = 209 [8%]); P = .03.
Main Outcome
The primary analysis demonstrated that oxygen supplementation did not significantly improve functional outcome at 90 days ( Figure 2) . The unadjusted OR for a better outcome (lower mRS) was 0.97 (95% CI, 0.89 to 1.05; P = .47) for combined oxygen vs control, and 1.03 (95% CI, 0.93 to 1.13; P = .61) for continuous oxygen vs nocturnal oxygen. Secondary analyses adjusted for With similar numbers of missing responses in the 3 groups (continuous oxygen, n = 101; nocturnal oxygen, n = 106; and control, n = 119), findings were much the same in sensitivity analyses using multiple imputation or analyzing only participants who adherered to protocol (eTable 3 in Supplement 3). Subgroup analysis ( Figure 3) found no indication that treatment effectiveness differed in any of the predefined subgroups, even those in whom most benefit might be expected such as patients with more severe stroke or those for whom oxygen supplementation was started early after stroke onset.
Secondary Outcomes
Analyses of secondary outcomes also showed no benefit from oxygen ( Table 2) . Neurological impairment at 1 week improved from baseline to the same degree in all 3 groups with median NIHSS scores of 2 (IQR, 1 to 6) by 1 week. Oxygen treatment did not increase the number of participants who were alive and independent or back in their home, the ability to perform basic (Barthel Index) or extended (Nottingham Extended Activities of Daily Living) activities of daily living, or quality of life (EuroQol-5D-3L) at 90 days. The results remained unchanged after adjustment for baseline prognostic factors (eTable 4 in Supplement 3). Mortality ( Figure 4 
Exploratory Analyses
There was no evidence of increased stress levels (higher heart rates, higher blood pressure, and need for sedation) in the oxygen-treated group than in the control group or evidence that oxygen treatment was associated with more infections, with little difference in the highest temperature or the need for antibiotics (Table 2) .
Safety Outcomes
The number of serious adverse events by 90 days was similar in the combined oxygen and control groups, but lower in the nocturnal oxygen group when compared with the continuous oxygen group (Table 2 ; eTable 5 in Supplement 3). No oxygen-related adverse events (respiratory depression, drying of mucous membranes) were reported.
Discussion
In this clinical trial of patients with acute stroke, routine prophylactic low-dose oxygen supplementation did not improve outcome among patients who were not hypoxic at baseline, whether oxygen was given continuously for 72 hours or at night only. This applied to the primary 90-day functional outcome and to all other tested outcomes, including early neurological recovery, mortality, disability, independence in basic and extended activities of daily living, and quality of life. The results remained unchanged in analyses adjusted for baseline prognostic factors and in sensitivity analyses using multiple imputation or analyzing adherers only. Subgroup analyses did not identify any characteristics that would make a patient more likely to benefit from oxygen treatment (includes enrollment between 3 to 6 hours after stroke onset, patients with a lower baseline oxygen saturation, severe strokes, a reduced level of consciousness, and a history of heart failure or lung disease [ie, characteristics for which benefit from oxygen was most anticipated]). Because of the large overall size of this trial, these patient subgroups were each sufficiently large for the lack of observed benefit to be likely real and not a false negative. In contrast to the much smaller SOS Pilot study, 15 this trial showed no evidence of better early neurological recovery with oxygen. Subgroup analysis of an earlier study of low-dose oxygen supplementation in acute stroke 14 suggested that oxygen might adversely affect outcome in patients with mild strokes, possibly through formation of toxic free radicals. A more recent study of short-burst high-flow oxygen (45 L/min) was terminated early (after enrollment of 85 patients) because of excess mortality in the actively treated group. 13 Hyperoxia was independently associated with mortality in a large retrospec- The x-axis depicts the common odds ratio (OR) for a better outcome over all 7 levels of the modified Rankin Scale score (mRS), derived from ordinal logistic regression. ORs greater than 1 indicate that a good outcome (low mRS) is more likely with oxygen than with control (reference category). The size of the markers reflects the total sample size in each subgroup, with larger markers indicating more precise estimates. The subgroup thresholds for oxygen concentration at randomization were revised from the prespecified thresholds because the analysis did not converge using the prespecified values. SSV indicates Six Simple Variable risk score; COPD, chronic obstructive pulmonary disease; GCS, Glasgow Coma Scale.
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Oxygen Supplementation After Acute Stroke tive cohort study of ventilated patients with stroke. 28 Although suggestive of potential harm, these findings could be due to confounding factors.
As a large pragmatic trial, this study included unselected patients with a clinical diagnosis of acute stroke without radiological confirmation. The sample therefore included ischemic and hemorrhagic strokes and participants who were later found to have mimics or transient ischemic attacks.
More than half of all acute stroke services in the United Kingdom participated, and wide inclusion criteria allowed enrollment of a representative sample of patients with ischemic and hemorrhagic stroke across the whole range of severity. Stroke severity was similar to that of the UK stroke population as a whole, with a median NIHSS of 5 in this trial and 4 in the UK Sentinel Stroke National Audit Programme, which includes every stroke patient admitted to UK hospitals. 29 The median NIHSS of 127 950 patients with acute ischemic stroke in the US Get with the Guidelines Register 30 was 5, as in this trial. A median NIHSS of 5 at baseline was also recorded in a large Dutch study of antibiotic prophylaxis after stroke, with similarly wide inclusion criteria. 31 This study has several limitations. Minor benefits from oxygen treatment might have been masked by poor adherence. However, this seems unlikely given the high statistical power to detect even small improvements. Moreover, sensitivity analyses did not show better outcomes in the adherersonly group (eTable 3 in Supplement 3). Furthermore, this trial found significant increases in the oxygen saturations in the treated groups compared with the control group. Patients with acute stroke are often restless and confused. Ensuring full adherence would ideally requirea1to1nurse-to-patient ratio. However, this is not possible outside an intensive care setting. The main outcome was assessed by postal questionnaire and supported by telephone interviews with nonresponders. This method has been used successfully in large pragmatic trials 32, 33 but has been replaced by remote multiple-rater video-recorded interviews or in-person interview and examination by an allocation-blinded rater using formal structured assessments in several more recent studies. 34 Low-dose oxygen supplementation may not be sufficient to prevent severe desaturations; both the SOS Pilot 15 and this trial found no significant difference in severe desaturations between the treatment and control groups. A small (N = 46) nonrandomized study comparing high-flow oxygen treatment via mask with low-flow supplementation via nasal cannula showed a trend toward lower mortality with high flow that was not statistically significant. However, evidence from randomized trials of high-flow oxygen treatment in acute stroke [11] [12] [13] does not show that higher doses of oxygen are associated with better outcomes. Early administration of high-dose oxygen might help maintain the viability of the ischemic penumbra and allow a broader time window for neuroprotection or thrombolysis. This question was not addressed in this trial of prophylactic oxygen, but will be tested in the PROOF trial. 35 The median time from stroke onset to randomization in this trial was 20 hours, 43 minutes. However, 101 participants were enrolled early (within 3 hours of symptom onset). Subgroup analysis (Figure 3) showed a similar lack of effect for oxygen in the small subset of patients enrolled early as in those enrolled later but was underpowered. Larger trials in the early time window would be needed to definitely exclude a benefit.
Conclusions
Among nonhypoxic patients with acute stroke, the prophylactic use of low-dose oxygen supplementation did not reduce death or disability at 3 months. These findings do not support low-dose oxygen in this setting. No. at risk Deaths
Continuous oxygen vs nocturnal oxygen
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Trial Summary
Mild hypoxia is common in stroke patients and may have significant adverse effects on the ischaemic brain after stroke. The use of oxygen treatment is rapidly increasing in European stroke units. A questionnaire survey of UK stroke physicians showed that almost 50% of respondents would start oxygen supplementation after stroke at a level of oxygen saturation of 95% or above, which is well within the normal physiological range. Oxygen treatment is not without side effects. It impedes early mobilisation, could pose an infection risk, and may encourage the formation of toxic free radicals leading to further damage to the ischaemic brain. A study of routine oxygen supplementation given for 24 h at a rate of 3L/min published in 1999 (Ronning and Guldvog) has shown no benefit in unselected patients, and potential harm in patients with mild strokes. In the Stroke Oxygen Pilot Study 64 65 the flow rate of oxygen was lower (2 or 3 L/min dependent on baseline oxygen saturation) and treatment was continued for longer (72 hours). Neurological recovery at one week was better in the oxygen group and after correction for difference in baseline stroke severity and prognostic factors there was a trend to better outcome with oxygen at 6 months. In contrast to the earlier study by Ronning and Guldvog oxygen was as effective in mild as in severe strokes. These results are promising, but need confirmation in a larger study.
Oxygen saturation is lower at night than during the day, and episodes of oxygen desaturation are common during sleep. Nocturnal oxygen supplementation is likely to reduce the burden of hypoxia without interfering with daytime mobilisation and rehabilitation.
Before wider use of oxygen supplementation becomes established it is important to obtain better evidence on which patients benefit from such treatment. SOS is a large 'real life' trial which aims to produce reliable evidence on the balance of benefits and risks for different patient groups by randomising a large number of patients to routine oxygen supplementation or no routine oxygen treatment. The information on a few thousand patients randomised in SOS will help to guide the treatment of many thousands of future patients.
To make recruitment of a large, heterogeneous group of patients practicable procedures are kept simple, and eligibility is based on 'uncertainty'. Patients admitted to hospital with an acute stroke for whom there is substantial uncertainty whether or not they should receive oxygen or not are randomised to continuous oxygen treatment, nocturnal oxygen treatment or standard therapy (no routine oxygen) for 72 hours. Oxygen will be given at a rate of 2 or 3 litres/minute depending on baseline oxygen saturation. In this trial the extra work for collaborators is absolutely minimal. In addition to the randomisation form there is a one page baseline assessment and a brief clinical review at one week. Outcome data at 3, 6 and 12 months will be by a questionnaire sent to the patient by the trial centre. The success of SOS depends on the wholehearted support of doctors involved in acute stroke management. For this reason, publication of the final results will be in the names of all the collaborators, and not those of the principal investigators. 
Background Why is there a need to investigate the effects of oxygen supplementation after stroke?
It is now well established that specialist care on stroke units is effective in preventing death and disability after stroke (1). It does, however, still remain unclear which aspects of stroke care are crucial for improving outcome. It has been shown that patients on a stroke unit are more likely to receive oxygen than on a non specialised general ward (2) . Mild hypoxia is common in stroke patients and may have significant adverse effects on the ischaemic brain after stroke (3) . Hypoxaemia in the first few hours after hospital admission is associated with an increased risk of death (4) . While healthy adults with normal cerebral circulation can compensate for mild hypoxia by an increase in cerebral blood flow (5), this is not possible in the already ischaemic brain after stroke (6) (7) (8) . The use of oxygen treatment is rapidly increasing in European stroke units. A questionnaire survey of UK stroke physicians showed that almost 50% of respondents would start oxygen supplementation after stroke at an oxygen saturation of 95% or above (9), which is well within the normal physiological range (10) . In many Accident and Emergency departments oxygen is given routinely to stroke patients irrespective of blood oxygen levels.
Oxygen treatment is not without side effects (11) . It impedes early mobilisation and could pose an infection risk. There is evidence from animal models and in vitro studies that oxygen encourages the formation of toxic free radicals leading to further damage to the ischaemic brain (12) (13) (14) (15) , especially during reperfusion. Marked changes in ATP and related energy metabolites develop quickly in response to acute ischaemia and tissue hypoxia. These alterations are only partially reversed on reperfusion despite improved oxygen delivery. Ischemia-induced decreases in the mitochondrial capacity for respiration result in reduced oxygen consumption and further increase free radical generation during reperfusion (16) . Oxidative stress has also been implicated in the activation of cell signalling pathways which lead to apoptosis and neuronal cell death (17, 18) While much research points towards adverse effects of hyperoxia in the ischaemic brain there is also evidence to support the notion that therapy-induced eubaric hyperoxia may be neuroprotective (19, 20) . Routine oxygen supplementation for acute myocardial infarction has been abandoned after a clinical trials showed no benefit, and potential harm (21) . A quasi randomised study of oxygen supplementation for acute stroke by Ronning and Guldvog has shown that routine oxygen treatment in unselected stroke patients does not reduce morbidity and mortality. Subgroup analyses suggested that patients with severe strokes were more likely to benefit than those with mild strokes, but the study size was too small to define patients who are likely to derive benefit with certainty (22) . A recent very small study of high flow oxygen treatment after acute stroke showed that cerebral blood volume and blood flow within ischaemic regions improved with hyperoxia. By 24 hours magnetic resonance imaging of the brain showed reperfusion in 50% of hyperoxia-treated patients versus 17% of controls (p=0.06) but no long term clinical benefit at 3 months (23). In the recently completed Stroke Oxygen Pilot Study 64 65 the flow rate of oxygen was lower (2 or 3 L/min dependent on baseline oxygen saturation) and treatment was continued for longer (72 hours). Neurological recovery at one week was better in the oxygen group than in controls. While there was no difference in outcome at 6 months on direct comparison, there was a trend for better outcome with oxygen after correction for differences in baseline stroke severity and prognostic factors. In contrast to the earlier study by Ronning and Guldvog oxygen was as effective in mild as in severe strokes. These results are promising, but need confirmation in a larger study.
Clinical guidelines on oxygen supplementation after stroke are not based on evidence from randomized clinical trials, differ from country to country and change over time without obvious reason. The European Stroke Initiative (2008) suggests that routine oxygen supplementation to all stroke patients has not been shown to be effective, but that adequate oxygenation is important, and that oxygenation can be improved by giving oxygen at a rate of >2 L/min (no target saturation or supporting evidence given). 66 The American Stroke Association Guideline recommended keeping the oxygen saturation at or above 95% in 2003, 24 there was no change to the recommendations in the 2005 update 25 of the guideline, but in 2007 the advice was revised to say that oxygen saturation should be maintained at or above 92%. 67 The latest UK National Clinical Guideline for the management of people with stroke (July 2008) 68 and the 2008 guidance from the National Institute for Clinical Excellence 69 state that supplemental oxygen should only be given in people who have had a stroke if the oxygen saturation falls below 95%. None of the recommendations are based on evidence from controlled clinical trials.
Not surprisingly, there is uncertainty amongst physicians treating patients with stroke about which treatment approach to take, and when to give oxygen, as shown by a recent survey of British Stroke Physicians (9) . For all the above reasons it is important to identify groups of patients who benefit from oxygen, and others who do not.
What is the justification for the fixed dose oxygen regime suggested for this study?
A fixed dosage scheme has been chosen to keep the design of the study as simple as possible, so that any recommendations resulting from the study outcome can be carried out in day to day clinical practice.
Ronning and Guldvog have shown that giving oxygen at a rate of 3L/min to all stroke patients during the first 24 hours after hospital admission does not improve overall outcome. They have not reported baseline oxygen saturation, or changes in saturation on treatment. It is therefore possible that some patients were undertreated, and others achieved too high oxygen levels leading to an increase in free radical generation in the ischaemic penumbra (28) . There are no other data from clinical studies to inform recommendations for the dose of oxygen to give. The recently updated European Stroke Initiative suggests a dose of 2-4 litres/minute (26), the American Stroke Association Guideline recommends to keep the oxygen saturation at or above 95% (24, 29) , but none is based on evidence from controlled clinical trials. In the absence of data to the contrary it is reasonable to assume that treatment should restore oxygen saturation to the normal range.
Normal oxygen saturation for adults is 95-98.5% (30) , in healthy older individuals it is lower at 95% ±2.5% (31). Oxygen saturation in stroke patients who are normoxic at recruitment is about 1% lower than that of age matched community controls (32) . We have just completed a dose titration study for oxygen after acute stroke and found that 2 L/min oxygen by nasal cannula increases oxygen saturation by 2% and 3 L/min by 3% (33) . We also found that oxygen masks were less likely to be tolerated than nasal cannulae, leading to poorer treatment compliance with the former. For this study we therefore decided to give oxygen by nasal cannula. A dosage regime of 3 litres per minute for individuals with a baseline oxygen saturation of ≤93% and 2 L/min for individuals with a baseline saturation >93% is likely to prevent hypoxia without increasing oxygen saturation beyond the upper limit of the normal range.
What are the advantages of giving routine oxygen supplementation at night only?
Patients are more likely to be hypoxic at night The mean nocturnal oxygen saturation is about 1% lower than awake oxygen saturation, both in stroke patients and controls (32) 
The development of hypoxia is more likely to be missed at night
It is more difficult to observe patients in the darkened room, and, unless there are reasons to suspect the patient is unwell, nurses will not waken the patient for routine observations. The development of hypoxia is therefore more likely to be missed at night.
Nocturnal hypoxaemia is more likely to lead to brain tissue hypoxia at night
A recent study in normal volunteers has shown that hypxoxaemia leads to a compensatory increase in cerebral blood flow during wakefulness, but not during sleep, and is therefore more likely to result in brain tissue hypoxia at night (37) .
Nocturnal oxygen supplementation does not interfere with the patient's daytime mobility
Early mobilisation is an important aspect determining good outcome (2) . Patients who are attached to monitoring equipment, or to oxygen supplementation are less likely to be mobilised than patients not attached to such equipment.
Giving routine oxygen at night only might prevent a significant number of otherwise undetected episodes of hypoxia without interfering with the patient's daytime rehabilitation.
Study aim and hypothesis
The aim of this study is firstly, to determine which patients will benefit from oxygen after stroke, and secondly to establish whether nocturnal oxygen supplementation is more effective than with continuous oxygen supplementation.
Main Hypothesis
Fixed dose oxygen treatment during the first 3 days after an acute stroke improves outcome after stroke.
Secondary hypothesis
Restricting oxygen supplementation to night time only is more effective than continuous supplementation.
Study protocol
Study design A multi-centre, prospective, randomized, open, blinded-endpoint study of routine oxygen supplementation after acute stroke versus no routine oxygen treatment.
Recruitment
Patients will be recruited from multiple (>30) centres throughout the UK and worldwide. The first study centre to be enrolled will be the University Hospital of North Staffordshire. Centres will be eligible for participation in the study if they admit patients with acute stroke, are able to provide oxygen treatment and monitor oxygen saturation, and if there is a local researcher who will act as the principal investigator for the locality.
Inclusion criteria
All adult patients with an acute stroke will be eligible to be considered for study participation. There are no definite guidelines for oxygen treatment after acute stroke, and there is
Hence adult patients will be eligible for trial inclusion if : They were admitted with symptoms of an acute stroke (e.g. symptom onset within 24 h or less of admission) within the preceding 24 hours, and in the doctor's opinion there is no clear indication for and no clear contraindication against oxygen treatment.
The diagnosis of stroke will be made by history and clinical examination and is at the discretion of the admitting doctor. It will based on the WHO criteria (rapidly developing clinical signs of focal or global disturbance of cerebral function, with symptoms lasting 24 hours or longer, or leading to death, with no apparent cause other than of vascular origin) (38) . Within the first 24 hours of symptom onset a definite distinction between a stroke and a transient ischaemic attack cannot be made. However, most patients who still have persistent symptoms after one hour will be confirmed to have a stroke. Since waiting for 24 hours for confirmation would unnecessarily delay treatment we omitted the time element from the definition of stroke for the purposes of trial inclusion.
Exclusion criteria
Patients will be excluded from the trial if the responsible doctor considers the patient to have definite indications for or contraindications to oxygen treatment at a rate of 2-3 L/min. The decision will be left to the responsible clinician. This exclusion criterion has been chosen to ensure that all patients are treated according to best medical practice.
Potential indications for oxygen treatment could be: oxygen saturation on air <90%, hypoxia associated with acute left ventricular failure, severe pneumonia, pulmonary embolus, and chronic respiratory failure patients treated with long term oxygen at home.
Potential contraindications to fixed dose oxygen treatment could be type 2 respiratory failure and very severe hypoxia.
Patients will also be excluded if the stroke is not the main clinical problem, or if he/she has another serious life-threatening illness likely to lead to death within the next few months. This group of patients is excluded because it is unlikely that they are going to derive any benefit from the trial treatment.
Intervention
Patients will be randomised into one of 3 treatment groups:
1. Treatment group 1: no routine oxygen supplementation during the first 72 hours after randomisation 2. Treatment group 2: oxygen per nasal cannula over night (21:00-7:00) at a flow rate of 3L/min (if baseline oxygen saturation is 93% or below) or at a flow rate of 2L/min (if baseline oxygen saturation is greater than 93%) during the first 3 nights after randomisation.
3. Treatment group 3: oxygen per nasal cannula continuously (day and night) at a flow rate of 3L/min (if baseline oxygen saturation is 93% or below) or a flow rate of 2L/min (if baseline oxygen saturation is greater than 93%) during the first 72 hours after randomisation. All patients will have regular observations of vital signs (blood pressure, heart rate, temperature and oxygen saturation) as per the local protocol of the stroke unit, but at least 6-hourly. Treatment of any abnormal findings will be independent of trial allocation. Patients who require oxygen or changes in the dose of oxygen for clinical reasons at any time of the trial will be given the concentration of oxygen they require.
Blinding
This study will be open, since placebo treatment (room air) would have similar side effects as the active treatment (e.g. infection and immobilisation), and would thus bias the data in favour of the treatment group. The main outcomes will be ascertained at 3 months by central follow-up, ensuring that the assessor is blind to the intervention. When the patients complete the questionnaire they may have some vague recollection of being treated with oxygen or not.
Patients will be asked to state on the questionnaire if they remember/can guess which treatment group they were in. This will then be compared with the actual allocation to quantify potential bias.
Initial assessment (see case record form) These will be done by the researcher randomizing the patient and entered on line for patients randomized via the web, and sent to the trial centre by fax for patients randomized via the telephone.
Baseline demographics, Date and time of event Glasgow Coma Scale (39) Predictors of outcome (40) NIHSS Stroke Scale (41, 42)
Follow-up Assessments
Week 1 (see week 1 follow-up form). The week one assessment will confirm the diagnosis, document deaths and neurological status (NIHSS), compliance with the intervention, and complications. It will be performed by a member of the local research team trained in the assessment tools 7 days (+/-1 day to allow for week ends and holidays) after enrolment. In patients who are discharged before the end of 1 week, or who can not be followed at 7 days, the patient will be assessed at discharge and if appropriate the follow-up completed at this time point. Wherever possible we will strive to assess the patient at day 7 after randomisation in hospital or, if discharged, in clinic or in their place of residence as the patient specifies. If 1 week assessment is not possible then the discharge assessment is acceptable as the 1 week outcome. Data will be entered on line or sent to the trial centre via fax.
3 months, 6 months, 12 months (see 3 month, 6 month and 12 month questionnaires)
The main follow-up will be performed centrally at 3 months, a standard procedure for most acute stroke trials. Assessments will be based on a questionnaire sent to the patient's preferred follow-up address by the central team after checking with the GP that the patient is still alive, unless the patient has specified a different preference at the week one assessment. Central follow up will ensure blinding of the assessors to the intervention. For non-responders the address will be checked via the GP and the local researcher and resent. If there is no response the patient will be contacted by phone to see if they preferred personal follow-up or were happy to reply to questions via the telephone. Missing or inconsistent data will be crosschecked with the medical notes, the GP or by personal contact with the patient. For patients who are not contactable via these methods we will determine if they have died and what the cause of death was by requesting information form the Office of National Statistics or the NHS Strategic Tracing Service. The latter will also be contacted if the patient is no longer resident at the address given, the GP has not seen the patient recently and does not know the contacts of the new address and new GP.
• Deaths (record date and cause of death) 
Outcome measures Primary Outcome
• Modified Rankin Score at 3 months (49) Secondary outcomes at one week
• No of patients with neurological improvement ( ≥4 point decrease in the NIHSS) (50)
• Any deaths All study measures will be performed by research staff appropriately trained in the use of the assessment tools. 
Data management and evaluation Randomisation
Patients will be randomized using minimised randomisation stratified by well validated prognostic factors (age, sex, living alone, normal verbal component of the Glasgow Coma Scale, ability to lift both arms, ability to walk) (52, 53) , routine oxygen treatment during ambulance transfer, and baseline oxygen saturation via a web based randomization system. Randomisation will not be stratified by study centre, because this may result in unacceptably high rates of allocation prediction and selection bias (54) . However, retrospective analysis by centre will be performed to investigate and adjust for any heterogeneity of treatment effect by centre.
Data management
The local investigators, their research assistants and data monitors will have access to the patient records. Personalized data (address, telephone number, email, fax) will be kept in the trial office and as electronic copies within each of the centres and at the coordinating centre to allow patients to be contacted for the 3, 6, and 12 month follow-up and to allow data checks and validation.
For all other purposes patient identifiable data will be converted to an alphanumerical code using a specific code number for each patient. The principal investigators, members of the trial steering group, the trial managers, data managers, data monitors, the data analysts/ programmers, and the trial statisticians will have access to the anonymised data.
Data will be stored on password protected office computers and on zip discs, flash drives or CD ROMs. At least 3 back up copies will be made of all data. These will be kept in locked cupboards in separate buildings.
Data will be transmitted via Fax, email or the Web from the each local centre to the trial coordinator and data queries will be transmitted via the same route from the trial coordinator to local centres. Anonymised data may be made available to other researchers for metaanalysis and publication in media such as the Cochrane Database.
Statistical analysis
The analysis will be by intention-to treat. The primary outcome is the modified Rankin Scale (mRS) score which has an ordinal range of 0 [best outcome] to 5 [worst outcome]. This will be measured at 3 months (or at the last rating). Deaths will be allocated an arbitrary score of 6 (55) . A later primary outcome assessment at 6 months was considered, but rejected because there is a risk of diluting treatment effects by newly occurring health problems unrelated to the trial intervention (56).
The trial tests two hypotheses: 1.
Oxygen supplementation results in better (i.e. lower) mRS scores at 3 months than no oxygen. 2.
Oxygen at night results in at least as good mRS scores as oxygen given over 24 hours.
It cannot be assumed that any benefits from oxygen will be dose dependent. Oxygen supplementation throughout the 24 hour periods may expose a significant number of patients to oxygen concentrations higher than normal. Being attached to oxygen may also limit mobility and hinder early mobilisation. Oxygen given at night only will provide supplementation at a time when oxygen saturation is lowest in stroke patients, and not interfere with rehabilitation. A prior hypothesis, therefore, is that oxygen at night will have all the potential advantages without disadvantages associated with daytime oxygen use.
The mRS will be compared between two groups using two sample t-tests. These assume a normal distribution and, to test this usually robust assumption, analyses will also be undertaken of the whole ordinal scale (57) by the Mann-Whitney U test using the software StatXact-4 (Cytel, Cambridge Mass.) or an equivalent. Ordinal logistic regression, with possible amalgamation of scores, will be used to assess the relationship between the mRS at 3 months with treatment groups, baseline oxygen saturation, whether the patient had been given oxygen before randomization or not, the prognostic factors (age, living alone before the stroke, independent pre-stroke, normal verbal response to questions, able to lift the affected arm against gravity, able to walk unaided) (52, 53) , the cause of stroke (haemorrhage/infarct), NIHSS score, and TOAST classification. Mortality will be assessed by using survival analysis.
Study size
Many acute stroke studies have been underpowered because the expected treatment effect was unrealistically large (58) . While thrombolysis within 3 hours of acute stroke has been shown to lead to moderate clinical benefits (0.5 Rankin point) (55), neuroprotectant treatments may well achieve lesser (e.g. 0.2 Rankin points) treatment effects (59) . Because stroke is such a common condition, and oxygen supplementation is inexpensive and universally available, even quite small differences in outcome could have a major impact on the burden of disease. For example, treating 5 patients with an average improvement of 0.2 mRS would improve one patient by one mRS category (e.g. from moderate disability to slight disability). However, though important, small differences do require very large trials to show effectiveness.
The sample size calculation is based on a mean mRS of 3.51 SD 2.03 [blind outcomes of the first 200 patients in the Stroke Oxygen Pilot Study (ISRCTN12362720) (60) ]. The sample size allows for a 5% drop-out rate (e.g. retrospective exclusions for change of diagnosis, numbers based on the Stroke Oxygen Pilot study) and a 5% rate of missing outcome data (gives a safe margin, target would be less than 3%). A sample size of 6000 patients will provide 90% power to detect small (0.2 mRS point) differences between oxygen (continuous and night only groups combined) and no oxygen at p<0.01, and 90% power at p<0.05 to detect small (0.2 mRS point) differences between continuous oxygen and oxygen at night only.
Added 03-10-2012: A sample size of 8000 patients will be used as increasing the recruitment target would give greater power to detect an interaction between subgroups (defined by severity) and the effect of oxygen versus control. The magnitude of the increase in power can be estimated by considering the increase in power to detect the pre-specified odds ratio of 0.83 in the subgroup of 'moderate through to very severe' patients (those with an NIHSS score greater than or equal to 10 and who are more likely to benefit from the treatment); power would rise from 43% to 50%. 
Ethical Requirements
Good Clinical Practice
The Study will be performed in accordance with the principles stated in the Declaration of Helsinki (61) . Study procedures will be guided by the standards outlined in the MRC Guidelines for Good Clinical Practice in Clinical Trials (62) .
Patient Information and Consent
Consent will be obtained according to the requirements of the Multicentre Research Committee and the Local Research Ethics Committees before the start of recruitment.
The patient, and where appropriate the next of kin, will be given full and adequate verbal and written information about the nature and purpose of the study, possible risks and benefits. A copy of the patient information sheet and the signed consent/assent will be given to the patient. The patient will be informed that they are free to discontinue participation in the study at any time.
Fully informed consent will be sought from all competent subjects. In patients who are conscious, but not fully competent the information to make a reasoned decision we will provide a simple explanation of the trial and seek the patient's agreement, but also seek assent from the next of kin or from an independent physician.. If an incompetent individual has been included in the trial without giving fully informed consent we will strive to obtain fully informed consent as soon as the patient is able to do so. This will be documented on the week one follow-up form.
The reasons for including patients unable to give fully informed consent: About one third of stroke patients will have problems with speech and with the understanding of spoken and written material as a consequence of their stroke. It is important to include these patients in the study since they are just as likely to benefit from the treatment as patients who are able to communicate.
It is further important to include as wide a spectrum of stroke patients as possible, in particular patients with severe strokes. Patients with severe strokes may be more likely to develop hypoxia, and may therefore be more likely to benefit from oxygen treatment than patients with mild strokes. However, patients with severe strokes are more likely to be confused, drowsy or dysphasic, and thus unable to give informed consent. Exclusion of subjects unable to give informed consent is thus likely to bias trial outcome. Furthermore, since the group of patients who is unable to consent has different clinical characteristics than patients who can give consent the results of the study may not be applicable to patients with similar clinical presentations to the excluded patients.
Patient/ relatives/ independent clinician information sheets:
The information sheets to be given to patients, relatives, or the independent clinician have been reviewed and edited by users from Strokes R Us (Stoke-on-Trent) and Different Strokes (Coventry).
Monitoring of suspected unexpected serious adverse reactions (SUSARs)
All suspected unexpected serious adverse reactions which are believed to be due to the trial treatment (SUSARs) will be reported as soon as possible within one working day of becoming aware of the event by phoning the study helpline (see contact details on page 5) or by emailing christine.roffe@northstaffs.nhs.uk. A SUSAR report form (http://www.so2s.co.uk/forms.shtml) will be completed as fully as possible and sent via fax, see contact details on page 5) to the Chief Investigator and the sponsor [North Staffordshire Combined Healthcare Trust Research and Development, see contact details on page 5]. On this form the patient will be identified by a unique identifying number consisting of the trial identification number (ISRCTN) followed by the number the patient was allocated at randomization. The SUSAR form will be filed in the trial master file and in the case record form. A SUSAR follow-up form will be competed as soon as possible within 5 days of the event and submitted via fax to the numbers above. This will also be filed in the trial master file and the case record form. Unless the event has resolved or a decision has been taken that no further follow-up is required, further follow-up forms will be completed, faxed and filed as outlined above until the event has resolved. Relevant details of the SUSAR and its follow-up will also be recoded in the patient's medical notes. The sponsor will inform the Licensing Authority, the Competent Authorities of any member state in whic h t h e t r i a l i s b e i n g conducted, and the relevant Research Ethics Committee (Research Ethics Committee, Mellor House, Corporation St, Stafford ST16 3SR, Fax 01785 254 640) of the SUSAR as soon as possible no later than 7 days after first becoming aware of the event. The sponsor will provide details of follow-up reports and resolution. The sponsor will also inform all the principal investigators of the trial of the SUSAR. At the end of each year from the start of the trial the sponsor will provide the Licensing authority (Medicines and Healthcare products Regulatory Authority, UK) with a list of all SUSARS relating to the trial during that year and any other The first trial protocol was designed and approved before funding was obtained. Early changes 4 reflect details of the NIHR RfPB grant. Further changes were related to change of funder to NIHR 5 HTA. Please find a listing of changes below. Changed sections are highlighted in yellow in the final 6 protocol for easier reference. 7
Title page (page 1): 8
Trial management group changed to trial management committee. Addition of trial manager and 9 patient and public representatives. 10 11 Updated to provide more detail, the SO 2 Ss website, and contacts of the trial team. 19 20 General information and contacts (page 5) 21
Updated to reflect changes in committee membership between the start and the end of the trial, 22 changes in contact details, and to include details of the sponsor, the funder and the research ethics 23 committee. 24 25 Background (pages 6-7) 26 Updated to include additional references relating to reperfusion and hyperoxia, the results of the 27 Stroke Oxygen Pilot Study, and national and international guidelines for the treatment of hypoxia. 28 29 Study protocol (pages 8-11) 30
Blinding: Details of blinding procedures added. 31 Initial assessment: More detailed instructions added. 32
Follow-up assessments: Follow-ups at 6 and 12 months added at the request of the funder (NIHR 33 RfPB) to determine if any improvements gained early were maintained over time. More detailed 34 information about processes relating to follow-up, blinding, and how to deal with non-responders. 35 Outcomes: the primary outcome (mRS) was moved from 6 months to 3 months to reflect changes in 36 stroke outcome assessment over time (3-month mRS is now one of the most commonly used 37 outcomes for stroke trials) (see page 12 of the final protocol for justification and references) and the 38 primary outcome for the RfPB funded start-up phase of the trial. NIHSS change at one week was 39 moved from a primary outcome to a secondary outcome, as it was considered that there should only 40 be one primary outcome. To limit the number of secondary outcomes (18 in the original protocol) 41 some of the outcomes (antibiotic use, sedative use, blood pressure, the outcomes generated by theeTable 1. Informed Consent Patients who were incompetent to give fully informed consent at randomization and were enrolled with consent from a relative, carer or independent legal representative were asked to confirm consent once competence was regained. This was documented for all participants at one week.
